Phase 2 N=48 Convalescent Plasma in the Treatment of COVID 19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · COVID · Coronavirus
Primary: Mortality — 19 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Convalescent Plasma for Patients With COVID-19
Coronavirus Infection · Coronavirus · COVID
Primary: Change in Respiratory Disease Severity — 251; 276 ratio
N/A N=200 Efficacy and Safety of COVID-19 Convalescent Plasma
Convalescent Plasma · COVID-19 · SARS-CoV 2
Primary: Duration of Oxygenation Support — 7.4 days
Early Phase 1 N=10 COVID-19 Convalescent Plasma
Coronavirus
Primary: Success of Administering Plasma — 10; 0 Participants
Phase 2 N=1,225 Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
SARS-CoV 2
Primary: Cumulative Number of Hospitalizations or Deaths Prior to Hospitalization — 17; 37 Participants — p=0.005
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants
Phase 2 N=180 Convalescent Plasma to Stem Coronavirus (CSSC-001)
Coronavirus · Convalescence
Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42
Phase 2 N=941 CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
COVID-19 · Coronavirus · Coronavirus Infection
Primary: Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 14 Days — 2; 2 score on a scale
Phase 3 N=117 Convalescent Plasma Collection and Treatment in Pediatrics and Adults
COVID19 · Coronavirus Infection · Coronavirus
Primary: Time of Meeting Infusion Criteria to Infusion — 1 days
Phase 2 N=131 Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
COVID-19
Primary: Overall Mortality — 22; 7 Participants
Phase 3 N=511 Convalescent Plasma in Outpatients With COVID-19
Covid19
Primary: Number of Patients With Disease Progression (Intention-to-treat Population) — 77; 81; 51; 56 Participants
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
Phase 1 N=32 COVID-19 Convalescent Plasma for Mechanically Ventilated Population
Covid-19
Primary: Participants With Serious Adverse Events. — 22 Participants
N/A N=5,044 Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
Coronavirus Disease 2019 (COVID-19)
Primary: All-cause Mortality — 40; 671 Person-trials
Phase 1 N=14 Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
SARS-CoV-2 Infection
Primary: Safety of Treatment With High-titer Anti-SARS-CoV-2 Plasma as Assessed by Adverse Events — 0 Participants
Phase 2 N=56 Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
COVID-19
Primary: Total Number of Serious Adverse Events (SAE) Through Study Day 14 — 0; 0 Serious Adverse Events
N/A N=55 Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
Covid19
Primary: Adaptive COVID-19 Treatment Trial Scale (ACTT) Version II — 0; 0; 0; 0 Participants
Phase 3 N=974 Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
COVID-19 · Coronavirus · SARS-CoV-2
Primary: COVID-19 7-point Ordinal Clinical Progression Outcomes Scale Score — 150; 144; 157; 167 Participants
N/A N=38 Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure
Primary: Survival — 9; 5 Participants
Phase 2 N=12 Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
COVID-19
Primary: NAb Dose Titer in the Convalescent Plasma (CP), Pre-treatment, and Day One in Hospitalized Patients With Documented COVID-19 Infection — 56.7; 390; 413 titer
Phase 2 N=34 Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
COVID-19 · Sars-CoV2
Primary: Mechanical Ventilation or Death Endpoint — 2; 0 Participants
Phase 3 N=606 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
Hemorrhagic Fever, Ebola
Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants
Phase 4 N=20 Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
COVID-19
Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP
Phase 3 N=593 Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
COVID · COVID-19 · SARS-CoV-2
Primary: Ordinal Outcome Scale - Day 7 — 5; 5; 9; 13 Participants
N/A N=3,443 IMPACT (Improving Plasma Collection) Clinical Trial
Apheresis Related Hypotension
Primary: Rate of Significant Hypotensive Adverse Events — .035; .051 % of significant hypotensive AEs
Phase 2 N=98 Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Phase 3 N=138 Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Influenza A Virus Infection
Primary: Clinical Status at Day 7 — 2; 2; 15; 10 Participants — p=0.54
Phase 2 N=23 Study of Plasma Exchange in Severe COVID-19
COVID19
Primary: Number of Participants With Inflammatory Marker Reduction of at Least 50% at Any Efficacy Time Point — 5; 8 Participants — p=0.16